Clinical Scorecard: Should Bone Scans Be Discontinued for Prostate Cancer Patients with PSA Levels of 20 ng/mL or Lower?

At a Glance

Key Highlights

• Bone metastasis occurs in 14.3% of newly diagnosed prostate cancer patients; higher incidence in Asian populations compared to Western data.
• Bone scans may be unnecessary for patients with serum PSA ≤ 20 ng/mL and Gleason score ≤ 7 according to AUA and EAU guidelines, but Asian populations may have higher positive bone scan rates within these criteria.
• Serum PSA, Gleason score, and clinical T stage are significant predictors of bone metastasis; sensitivity and specificity vary with PSA cutoff levels.

Guideline-Based Recommendations

Diagnosis

• Perform bone scans for detection of bone metastasis in prostate cancer patients, especially with PSA > 20 ng/mL or Gleason score > 7.
• Consider omitting bone scans in patients with serum PSA ≤ 20 ng/mL and Gleason score ≤ 7 per AUA and EAU guidelines, but evaluate population-specific data.

Management

• Use bone scan results to guide treatment strategy, particularly to identify occult locoregionally advanced or distant metastatic disease.
• Apply clinical judgment in populations with higher incidence of bone metastasis at lower PSA levels.

Monitoring & Follow-up

• Monitor PSA levels and Gleason scores as predictors for bone metastasis risk.
• Use imaging follow-up if bone scan findings are unclear, including CT or MRI.

Risks

• Bone scans are expensive and time-consuming; unnecessary scans increase healthcare costs without benefit.
• Risk of missing bone metastasis if bone scans are omitted in patients with PSA ≤ 20 ng/mL and Gleason score ≤ 7, especially in Asian populations.

Patient & Prescribing Data

579 consecutive newly diagnosed prostate adenocarcinoma patients undergoing bone scans

21 patients (3.6%) with PSA ≤ 20 ng/mL and Gleason score ≤ 7 had positive bone scans, indicating a non-negligible risk of bone metastasis despite low PSA and Gleason scores.

Clinical Best Practices

• Assess PSA level, Gleason score, and clinical T stage collectively to predict bone metastasis risk.
• Consider ethnic and regional differences in PSA distribution and prostate cancer epidemiology when applying guidelines.
• Confirm unclear bone scan results with additional imaging modalities such as CT or MRI.
• Balance cost and benefit when deciding on bone scan necessity, especially in patients with low PSA and Gleason scores.

References

• American Urologic Association (AUA) Guidelines
• European Association of Urology (EAU) Guidelines
• Japanese Urological Association Clinical Guidelines 2006